Bolt Biotherapeutics, Inc. - Schedule 13D/A Filing Summary

This filing details amendments to the Schedule 13D for Bolt Biotherapeutics, Inc., reporting changes in beneficial ownership as of February 26, 2026. Pivotal bioVenture Partners Fund I, L.P. and its affiliates reported a beneficial ownership of 52,556 shares, representing 2.7% of the class. This marks a decrease from previous holdings, as the reporting persons ceased to be the beneficial owners of more than five percent of the Common Stock on February 24, 2026. The filing also includes details of transactions over the past sixty days, primarily sales of common stock by Pivotal bioVenture Partners Fund I, L.P. and NFLS Beta Limited, with weighted average prices ranging from $4.50 to $5.25. The total number of outstanding shares of Common Stock was reported as 1,919,441 as of November 12, 2025.